Table 3.
[11C]PBR28 SA-IRF voxel-wise estimates at baseline and after administration of blocking drug
| ROI | IRF estimates (min−1) | ||
|---|---|---|---|
| Baseline (Mean ± SD) | Blocking (Mean ± SD) | Mean Rel Diff | |
| Whole brain | 0.106 ± 0.025 | 0.065 ± 0.011 | 39 % |
| Occipital lobe | 0.096 ± 0.015 | 0.057 ± 0.009 | 40 % |
| Temporal lobe | 0.090 ± 0.025 | 0.056 ± 0.009 | 38 % |
| Frontal lobe | 0.120 ± 0.036 | 0.074 ± 0.013 | 38 % |
| Parietal lobe | 0.101 ± 0.024 | 0.060 ± 0.011 | 40 % |
| Insular cortex | 0.124 ± 0.036 | 0.072 ± 0.015 | 42 % |
| Cingulate cortex | 0.129 ± 0.035 | 0.078 ± 0.011 | 39 % |
| Thalamus | 0.121 ± 0.029 | 0.080 ± 0.014 | 34 % |
| Hippocampus | 0.105 ± 0.024 | 0.064 ± 0.008 | 39 % |
| Striatum | 0.117 ± 0.032 | 0.069 ± 0.015 | 41 % |
| Cerebellum | 0.118 ± 0.028 | 0.071 ± 0.016 | 40 % |
The statistical difference between the two conditions was tested and found statistically significant for each ROI (p < 0.05)